Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 20/20 | 1.00 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607645 | 0.90 | CRHR1 (1.00) | CRHR1CRHR2LMNA | |
| SCHEMBL6605478 | 0.83 | CRHR1 (1.00) | CRHR1MEN1LMNAMAPK1KMT2A | |
| SCHEMBL6605011 | 0.82 | CRHR1 (1.00) | CRHR1LMNATSHR | |
| SCHEMBL6607652 | 0.80 | CRHR1 (0.67) | CRHR1 | |
| SCHEMBL6621349 | 0.80 | CRHR1 (0.66) | CRHR1 | |
| SCHEMBL6928652 | 0.79 | CRHR1 (1.00) | CRHR1LMNAMAPK1KMT2A | |
| SCHEMBL6607221 | 0.73 | CRHR1 (0.69) | CRHR1MEN1LMNAKMT2ANPSR1 | |
| SCHEMBL772599 | 0.70 | CRHR1 (0.68) | CRHR1 | |
| SCHEMBL6606399 | 0.67 | CRHR1 (1.00) | CRHR1CRHR2 | |
| SCHEMBL6606583 | 0.66 | CRHR1 (0.61) | CRHR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320365-A4 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL MYERS SQUIBB CO (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1320365-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | Bristol-Myers Squibb Company (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6515005-B2 | For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002024200-A1 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161019-A1 | Substituted azole derivatives as inhibitors of corticotropin releasing factor | CRH, CRHR1, CRHR2 | CRHR1 2/4885CRHR2 3/4885MEN1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.